Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorde...( Initial Results Expected...),Health

Initial Results Expected to be Reported in Q2 2008

MOUNTAIN VIEW, Calif., April 30 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has completed the enrollment in its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in patients with panic disorder. AZ-002 is an inhalation product candidate being developed for the acute treatment of panic attacks associated with panic disorder. AZ-002 is being developed through Symphony Allegro, a development collaboration formed between Alexza and Symphony Capital in 2006.

The AZ-002 Phase 2a clinical trial was an in-clinic proof of concept study. It was a four-center, randomized, double-blind, placebo-controlled evaluation of 49 patients with panic disorder. The primary aim of the clinical trial was to assess the safety and efficacy of a single dose of AZ-002 in treating a pharmacologically-induced panic attack. Differences versus placebo in the intensity and the duration of a panic attack, measured at multiple time points during the study using psychological and physiological measurements, will be used to assess the safety and efficacy of AZ-002. Alexza projects that the initial results will be reported before the end of Q2 2008.

About Panic Attacks

According to the National Institute of Mental Health, approximately 2.4 million people in the United States suffer from panic disorder, a condition characterized by the frequent and sudden occurrence of panic attacks. The physical and emotional symptoms of a panic attack have many variations, but often begin rapidly, peak within 10 minutes and last about 30 minutes. There are currently no drugs approved for the acute treatment of panic attacks. Ora
'/>"/>